Pfizer Halts Danuglipron Obesity Pill Trials
April 14, 2025
-
3 min
Pfizer has discontinued the development of danuglipron, a potential weight-loss agent, due to a suspected drug-induced liver injury in a clinical trial participant. The company had been testing multiple doses of the oral drug as a more convenient alternative in the competitive weight-loss drug market. This discontinuation has led to significant stock movement and may prompt Pfizer to pursue partnerships in the near term.
1. Pfizer discontinues development of the weight-loss agent danuglipron due to suspected drug-induced liver injury in a clinical trial. 2. The discontinuation impacted stock prices and may prompt Pfizer to pursue partnerships. 3. Danuglipron was being tested as a potential more convenient alternative in the competitive weight-loss drug market. 4. Novo Nordisk's Wegovy and Eli Lilly's Zepbound currently dominate the market. 5. Pfizer may focus on its investigational oral agent targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR).
Listen Tab content
